Jane Street Group LLC Sells 97,690 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Jane Street Group LLC reduced its stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 19.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 406,587 shares of the company's stock after selling 97,690 shares during the period. Jane Street Group LLC owned approximately 0.28% of Adaptive Biotechnologies worth $2,437,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of ADPT. KBC Group NV acquired a new stake in shares of Adaptive Biotechnologies in the fourth quarter valued at approximately $50,000. Cibc World Markets Corp acquired a new position in Adaptive Biotechnologies during the fourth quarter worth $65,000. Amundi increased its holdings in Adaptive Biotechnologies by 41.2% during the fourth quarter. Amundi now owns 15,532 shares of the company's stock worth $93,000 after buying an additional 4,531 shares during the last quarter. Proficio Capital Partners LLC acquired a new position in Adaptive Biotechnologies during the fourth quarter worth $93,000. Finally, Walleye Capital LLC bought a new position in Adaptive Biotechnologies during the fourth quarter worth $94,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Adaptive Biotechnologies news, insider Harlan S. Robins sold 68,412 shares of the stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $7.35, for a total value of $502,828.20. Following the completion of the sale, the insider now owns 1,279,524 shares in the company, valued at approximately $9,404,501.40. This trade represents a 5.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Chad M. Robins sold 211,160 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $8.50, for a total transaction of $1,794,860.00. Following the transaction, the chief executive officer now directly owns 2,576,701 shares of the company's stock, valued at $21,901,958.50. This represents a 7.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 667,092 shares of company stock worth $5,198,980 in the last quarter. Insiders own 6.40% of the company's stock.

Adaptive Biotechnologies Stock Performance

Shares of NASDAQ ADPT traded up $0.15 during trading on Monday, hitting $9.20. 1,033,664 shares of the company traded hands, compared to its average volume of 1,573,360. The business's fifty day moving average is $8.03 and its 200 day moving average is $7.23. Adaptive Biotechnologies Co. has a fifty-two week low of $2.99 and a fifty-two week high of $10.28. The firm has a market capitalization of $1.40 billion, a price-to-earnings ratio of -8.44 and a beta of 1.75.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.08. Adaptive Biotechnologies had a negative net margin of 89.12% and a negative return on equity of 64.65%. The firm had revenue of $52.44 million for the quarter, compared to analyst estimates of $42.13 million. During the same quarter in the prior year, the business earned ($0.33) earnings per share. The business's quarterly revenue was up 25.2% compared to the same quarter last year. On average, analysts predict that Adaptive Biotechnologies Co. will post -0.92 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on ADPT shares. Piper Sandler reaffirmed an "overweight" rating and set a $13.00 price objective (up previously from $11.00) on shares of Adaptive Biotechnologies in a research report on Tuesday, May 6th. The Goldman Sachs Group lifted their price target on shares of Adaptive Biotechnologies from $9.00 to $10.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Morgan Stanley boosted their price objective on shares of Adaptive Biotechnologies from $7.00 to $9.00 and gave the stock an "equal weight" rating in a research note on Monday, May 5th. Finally, Scotiabank boosted their price objective on shares of Adaptive Biotechnologies from $10.00 to $12.00 and gave the stock a "sector outperform" rating in a research note on Thursday, February 13th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $9.83.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.